← Back to all signals
RESEARCH PAPER ANALYSIS

Structural Volumetric Alterations in Parkinson's Disease With Mild Cognitive Impairment.

Meta-analysis shows PD-MCI patients have significant atrophy in hippocampus, thalamus, putamen, amygdala and right-lateralized globus pallidus compared with cognitively normal PD, while caudate volumes are preserved.

PMID42043968
JournalBrain and behavior
Publication Date2026-05-01
Ingested2026-04-28 08:58 PM
EXECUTIVE SUMMARY

What the AI sees

Meta-analysis shows PD-MCI patients have significant atrophy in hippocampus, thalamus, putamen, amygdala and right-lateralized globus pallidus compared with cognitively normal PD, while caudate volumes are preserved.

WHY IT MATTERS

Research significance

Identifies a reproducible subcortical imaging signature that could serve as a biomarker for early cognitive decline and trial enrichment in PD, but offers limited direct mechanistic or therapeutic leads for drug discovery.

ABSTRACT

Source abstract

BACKGROUND: Parkinson's disease with mild cognitive impairment (PD-MCI) is a critical dementia prodrome, but its structural neuropathology remains incompletely defined. While hippocampal atrophy is established, volumetric changes in other subcortical structures are poorly characterized. OBJECTIVE: To perform the first comprehensive meta-analysis quantifying gray matter volume alterations across six subcortical regions in PD-MCI. METHODS: A systematic search of PubMed, Web of Science, Embase, and Cochrane (inception-June 2025) for studies reporting MRI volumetric data comparing PD-MCI and cognitively normal PD (PD-NC) was done. Random-effects models calculated pooled weighted mean differences (WMDs) with 95% confidence intervals (CIs). Heterogeneity (I2), publication bias, sensitivity analyses, and meta-regression were assessed. RESULTS: PD-MCI showed significant bilateral atrophy versus PD-NC in the hippocampus (total WMD = -0.65 cm3), thalamus, putamen, and amygdala, alongside right-lateralized globus pallidus atrophy (WMD = -0.08 cm3). Bilateral caudate nuclei volumes were preserved. Sensitivity analyses confirmed robustness. Meta-regression identified segmentation tools and country as sources of left hippocampal heterogeneity (p < 0.05). No publication bias was detected. CONCLUSION: PD-MCI exhibits a distinct subcortical atrophy signature involving limbic-striato-thalamic networks, with right globus pallidus atrophy as a novel lateralized biomarker. Network-based imaging paradigms are advocated, requiring standardized protocols and longitudinal validation. SYSTEMATIC REVIEW REGISTRATION: Identifier PROSPERO (CRD420251051275).

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 The cGAS-STING-Glymphatic-gut Axis in Parkinson's disease: A proposed self-amplifying triad of Neuroinflammation and therapeutic opportunity. International immunopharmacology 91.0 2 Immunosenescence and Inflammaging as Drivers of Neurodegeneration: Cellular Mechanisms, Neuroimmune Crosstalk, and Therapeutic Implications. Cells 91.0 3 Flavonoids improve neurotransmitters for Parkinson's treatment: mechanism and therapeutic potential. Frontiers in pharmacology 88.0 4 Alpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives. Neurology international 78.0 5 The Gut Microbiota in Parkinson's Disease: Mechanistic Insights into Microbial-Host Interactions. Microorganisms 85.0 6 Linking inflammation, metabolic dysfunction, and neurodegeneration: a comprehensive review of TLR2 pathways in type 2 diabetes. Frontiers in clinical diabetes and healthcare 80.0 7 Neuroprotective effects of GLP-2 and a GLP-2/GIP dual receptor agonist in an MPTP-induced mouse model of Parkinson's disease. Peptides 86.0 8 TNF alpha unmasks enteric malate aspartate shuttle dysfunction bridging Parkinson disease and intestinal inflammation. Nature communications 91.5 9 Lipid Metabolism and Neurodegeneration: Mechanistic Insights and Therapeutic Targets. Ageing research reviews 82.0 10 Shared functional microbiome signatures in Parkinson's disease and constipation predominate irritable bowel syndrome despite taxonomic divergence. Brain, behavior, & immunity - health 80.0 11 Benzimidazole as a Versatile Scaffold for Developing Neurotherapeutics Against Neurodegenerative Diseases. ChemMedChem 74.0 12 Biomimicking neuromelanin reverses the gait deficits and dopaminergic neuronal loss in the Parkinson's disease. Colloids and surfaces. B, Biointerfaces 86.0 13 Neuroprotective roles of klotho: Molecular pathways and therapeutic implications for cognitive health in neurological and psychiatric diseases. Experimental physiology 84.0 14 Flavonoid Rutin Reduces Intestinal Inflammation in an Experimental Model of Parkinson's Disease. Neurotoxicity research 70.0 15 Nanostructured Lipid Carriers Enhance Brain Delivery and Antioxidant Efficacy of a Small-Molecule MAO B Inhibitor for Neurodegenerative Disease Therapy. Molecular pharmaceutics 78.0 16 Pathophysiological Role of the Gut Brain Axis in Parkinson's Disease: From Microbial Metabolites and Intestinal Permeability to Central Neuroinflammation. Current neurovascular research 86.0 17 Parkinson's Disease: From Metabolism to Genetics-A Comprehensive Review. Current issues in molecular biology 86.0 18 Navigating the cholesterol maze: Key insights on use of statins in neurodegenerative disorders. Neuroprotection (Chichester, England) 76.0 19 Integrative network pharmacology delineates dual GPCR and non-GPCR mechanisms of blended and individual Taikong Blue lavender and Pingyin rose essential oils in neurodegenerative and psychiatric disorders. Computers in biology and medicine 65.0 20 Models of neuroprotection in Parkinson's disease: Exploring cellular, molecular, and microenvironmental targets. Experimental neurology 78.0 21 Hyaluronic acid: emerging roles and biomaterial innovations in Alzheimer's and Parkinson's disease therapy. Frontiers in pharmacology 75.2 22 Molecular mechanisms underlying Parkinson's disease and role of phytochemicals, α-synuclein, sirtuins, and incretin mimetics in potential therapy. Frontiers in pharmacology 75.0 23 Lipid droplets in neurodegenerative diseases: pathological drivers and therapeutic vulnerabilities. Cell death discovery 82.0 24 Brain-gut-microbiota axis: a review on the bidirectional regulatory mechanisms between gut microbiota and brain and their disease interactions. Frontiers in microbiology 74.0 25 Long non-coding RNAs in neurodegenerative diseases - Molecular mechanisms, liquid biopsy biomarkers, and therapeutic targets: A review. Biomolecules & biomedicine 84.0 26 Neurosyphilis and Parkinsonism: Overlapping Pathophysiology and Emerging Therapeutic Insights. Current neurovascular research 76.0 27 Molecular biochemistry of soluble epoxide hydrolase in lipid mediator pathways and neuroinflammatory responses. The Journal of steroid biochemistry and molecular biology 82.0 28 Multifaceted role of CNPY2 beyond ER stress: Disease implications and therapeutic potential. Cell stress 83.3 29 Neuroprotective Role of Exercise-based Physiotherapy Combined with Pharmacological Agents in Parkinson's Disease. Central nervous system agents in medicinal chemistry 64.0 30 Distinct metabolomic and proteomic signatures in Parkinson's disease patients with REM sleep behavior disorder. Signal transduction and targeted therapy 84.0 31 HMGB1-mediated neuroinflammation: molecular mechanisms and emerging therapeutic approaches. Inflammopharmacology 78.0 32 Beyond acid-base dyshomeostasis: Dynamic instability of neuronal lysosomal pH as a pathogenic mechanism and therapeutic target in neurological diseases. Biochemical pharmacology 88.0
Neurocompute Parkinson’s Narrative Velocity Infographic
NEUROCOMPUTE VISUAL SYSTEM

Open the Narrative Velocity Map

Explore the full Parkinson’s research intelligence diagram.

Expand Intelligence View →
Full Neurocompute Infographic